Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/

领导和运营中心（LOC）、艾滋病临床试验组（ACTG）；

• 批准号: 10182391
• 负责人: Judith S. Currier
• 金额: $ 18194.26万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-24 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10182391
• 关键词: AIDS clinical trial group; COVID-19; Centers for Disease Control and Prevention (U.S.); Clinic; Clinical Trials Cooperative Group; Enrollment; HIV; Infection Control; Leadership; Location; Measures; Participant; Patients; Phase; Population; Prevention; Protocols documentation; clinical research site; coronavirus disease; operation; phase III trial; prevention clinical trial

To more safely and efficiently treat COVID-19 participants, we request support to place COVID-19 Isolation PODS at 14 of the ACTG CRSs. The storage company, PODS, has developed stand-alone and CDC compliant units. Installation of a COVID-19 POD at CRS locations will primarily facilitate A5401 but also protocol A5395. These units additionally allow separation between these activities and our HIV patients for both COVID treatment and prevention studies. A5401 will study up to 10 different agents across phase 2 and phase 3 trials. This dedicated space will allow for efficient treatment of a high volume of study participants without comprising infection control measures of the general clinic population.

为了更安全，有效地对待Covid-19参与者，我们请求支持将COVID-19隔离舱放置在ACTG C​​RS的14个。存储公司PODS已开发了独立和CDC符合的单元。 在CRS位置安装COVID-19 POD将主要促进A5401，但也将协议A5395促进。这些单位还允许这些活动与我们的HIV患者进行互联治疗和预防研究。 A5401将在2阶段和第3阶段试验中研究多达10种不同的代理。这个专门的空间将允许有效地治疗大量的研究参与者，而无需包括一般诊所人群的感染控制测量。